CD274 and non-small cell lung carcinoma: More recently, tumor mutational burden (TMB), defined as the number of non-synonymous mutations per coding area of tumor genome, has become a useful predictive marker for ICB effectiveness, regardless of PD-L1 expression, in different types of solid tumors, including NSCLC [17,18].